Searchable abstracts of presentations at key conferences in endocrinology

ea0024p1 | (1) | BSPED2010

Adverse drug reactions and corticosteroids in acute paediatric admissions

Gallagher R M , Mason J R , Bird K A , Turner M A , Smyth R L

Introduction: Adverse drug reactions (ADRs) are a significant cause of morbidity in childhood. We undertook a prospective study to investigate ADRs causing admission to a UK paediatric hospital: this report focuses on corticosteroids (CS).Methods: Three investigators assessed all acute admissions over a 1 year period and identified ADRs by cross-referencing clinical presentations to known ADR profiles using a standardised causality tool.<p class="abs...

ea0031oc4.8 | Obesity, metabolism and bone | SFEBES2013

Peptide YY regulates bone mineral content and strength

Brassill M J , Rahman S A , Boyde A , Batterham R L , Williams G R , Assett J H D B

Bone loss in anorexia nervosa and following bariatric surgery is associated with an elevated circulating concentration of the gastrointestinal anorexigenic hormone peptide YY (PYY), which acts principally via the Y1R and Y2R receptors. Selective deletion of Y1R in osteoblasts or Y2R in the hypothalamus results in high bone mass, but deletion of PYY has resulted in conflicting skeletal phenotypes leading to uncertainty regarding its role in the regulation of bone mass. We hypot...

ea0026p265 | Pituitary | ECE2011

Pasireotide (SOM230) demonstrates efficacy in patients with Cushing’s disease: results from a large, randomized-dose, double-blind, Phase III study

Colao A , Petersenn S , Newell-Price J , Findling J W , Gu F , Maldonado M , Schoenherr U , Mills D , Salgado L R , Biller B M K

Introduction: Pasireotide is a multi-receptor targeted somatostatin analogue with high affinity for sst5, which is commonly expressed in corticotroph adenomas, thus having potential as therapy for Cushing’s disease.Methods: One hundred and sixty-two patients with persistent/recurrent or de novo (if not surgical candidates) Cushing’s disease were randomized (double-blind) to pasireotide 600 μg (n=82) or 900 μg ...

ea0026p284 | Pituitary | ECE2011

Improvement in clinical signs and symptoms of Cushing’s disease following 12 months' pasireotide therapy

Pivonello R , Newell-Price J , Findling J W , Gu F , Maldonado M , Schoenherr U , Mills D , Salgado L R , Biller B M K

Introduction: The multi-receptor targeted somatostatin analogue pasireotide has demonstrated efficacy in reducing cortisol in patients with Cushing’s disease in a large, randomized, double-blind, Phase III study. The effects of pasireotide on the signs and symptoms of Cushing’s disease were also investigated as secondary objectives in this trial.Methods: Adult patients with persistent/recurrent or de novo Cushing’s disease were rand...